Tonix: Horsepox virus showed protection vs. lethal vaccinia infection in study
Tonix Pharmaceuticals Holding announced the publication of research describing the successful synthesis and characterization of a potential smallpox-preventing vaccine based on horsepox virus. The research was conducted in conjunction with scientists from the University of Alberta, a leading Canadian research university. The peer-reviewed article, "Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments published in the journal PLOS ONE, follows the announcement in March of 2017 of the complete synthesis of horsepox virus using synthetic biology technology. The synthetic horsepox virus demonstrated the ability to protect against lethal vaccinia infection in a mouse model which may be indicative of vaccine protection in humans. Tonix is developing the synthetic version of horsepox virus from cell culture, designated TNX-801, as a potential vaccine to prevent smallpox infection in humans. TNX-801 is at pre-Investigational New Drug application stage.